Yale Bulletin and Calendar

October 8, 2004|Volume 33, Number 6

Researchers discover VEGF molecule
plays key role in asthma

In a whole new approach to asthma research, scientists at Yale have discovered that a molecule called Vascular Endothelial Growth Factor (VEGF) likely plays an important role in the development of the disease and raises the possibility of new asthma drugs that block VEGF receptors and signaling pathways.

VEGF is normally associated with the growth of new blood vessels in the lungs and other organs. Yale researchers found, however, that in addition to this function, VEGF can also induce asthma-like abnormalities in the airway. When VEGF is expressed in the lungs of genetically engineered "transgenic" mice, asthma-like alterations develop, according to a report in the journal Nature Medicine.

"In humans with asthma, there is an increased level of VEGF, so we mimicked this condition in mice by over-expressing VEGF in their lungs," said principal investigator Dr. Jack A. Elias, section chief of pulmonary and critical care medicine at the School of Medicine. "To our surprise, in addition to growing new blood vessels, many other features of asthma were also seen in these mice. We saw mucous formation, airway fibrosis and asthma-like pulmonary function abnormalities. We also found that if you block VEGF, you block the asthma-like manifestations in other mouse asthma models."

Previous studies showed that people with allergies and asthma have an excess of T-helper type 2 cells (TH2). Elias and his team found that when VEGF is produced, the TH2 response is increased.

A high percentage of people with asthma have allergies. They also have a higher tendency to become allergic to particles and antigens to which they are exposed. Normal individuals become tolerant to the same agents, instead of becoming allergic. "The reason why some people develop this tolerance and others don't has never been understood," Elias said. "We found that this tolerance is broken in the genetically-engineered transgenic mice, suggesting that the VEGF-induced break in tolerance contributes to the allergic sensitization of asthmatic patients."

Elias and his team are currently examining how VEGF works at the cellular and molecular levels. These latest findings add to the growing body of research from Elias's lab that has advanced knowledge of asthma, a rapidly increasing chronic lung condition, which affects millions of people around the world.

Other authors on the study include Dr. Chun Geun Lee, Dr. Holger Link, Dr. Robert J. Homer, Dr. Svetlana Chapoval, Dr. Vineet Bhandari, Dr. Min Jong Kang, Dr. Lauren Cohn and Dr. Yoon Keun Kim, all of Yale; and Peter Baluk and Dr. Donald M. McDonald of the University of California-San Francisco.

-- By Karen Peart

T H I SW E E K ' SS T O R I E S

Andrew Hamilton named Yale Provost

Yale rated tops in Fulbright grant winners

Program marks 35 years of helping youngsters succeed in school

Interest in community building, world of theater . . .

Story of a 'solitary yellow in a white world' is tale of hope, says Koh

Yale Employee Day at the Bowl will feature free giveaways

This year's Divinity School Convocation features concert . . .

Event explores the future of Judaism

Design icon William Morris is focus of new exhibit

Event celebrates law professor's scholarly work

Physical basis of hereditary pain syndrome identified

Study reveals crucial role of lipid in synaptic transmission

Model shows most recent common ancestor of today's humans . . .

Researchers discover VEGF molecule plays key role in asthma

Dr. Martin Gordon wins medical school honor

Engineer T.P. Ma recognized for his scientific accomplishments

Martin Saunders is cited by the American Chemical Society

Sherwin receives award for efforts in diabetes treatment, research

Memorial service for Dr. Frederick Redlich

Campus Notes